![Algorithms | Free Full-Text | Sybil in the Haystack: A Comprehensive Review of Blockchain Consensus Mechanisms in Search of Strong Sybil Attack Resistance Algorithms | Free Full-Text | Sybil in the Haystack: A Comprehensive Review of Blockchain Consensus Mechanisms in Search of Strong Sybil Attack Resistance](https://pub.mdpi-res.com/algorithms/algorithms-16-00034/article_deploy/html/images/algorithms-16-00034-g001.png?1674201899)
Algorithms | Free Full-Text | Sybil in the Haystack: A Comprehensive Review of Blockchain Consensus Mechanisms in Search of Strong Sybil Attack Resistance
![Sustainability | Free Full-Text | An ISM Modeling of Barriers for Blockchain/Distributed Ledger Technology Adoption in Supply Chains towards Cybersecurity Sustainability | Free Full-Text | An ISM Modeling of Barriers for Blockchain/Distributed Ledger Technology Adoption in Supply Chains towards Cybersecurity](https://pub.mdpi-res.com/sustainability/sustainability-13-04672/article_deploy/html/images/sustainability-13-04672-g001-550.jpg?1619087215)
Sustainability | Free Full-Text | An ISM Modeling of Barriers for Blockchain/Distributed Ledger Technology Adoption in Supply Chains towards Cybersecurity
![Cancers | Free Full-Text | Targeting TET2 as a Therapeutic Approach for Angioimmunoblastic T Cell Lymphoma Cancers | Free Full-Text | Targeting TET2 as a Therapeutic Approach for Angioimmunoblastic T Cell Lymphoma](https://pub.mdpi-res.com/cancers/cancers-14-05699/article_deploy/html/images/cancers-14-05699-g001-550.jpg?1669112262)
Cancers | Free Full-Text | Targeting TET2 as a Therapeutic Approach for Angioimmunoblastic T Cell Lymphoma
![Cancers | Free Full-Text | Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Cancers | Free Full-Text | Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary](https://www.mdpi.com/cancers/cancers-13-04008/article_deploy/html/images/cancers-13-04008-g003.png)
Cancers | Free Full-Text | Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary
![Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children | Science Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children | Science](https://www.science.org/cms/10.1126/science.abo3627/asset/c7f24f7f-5455-46b5-935e-9bc50b2645b4/assets/images/large/science.abo3627-fa.jpg)